Paul S. S Aisen

Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease

Early-onset Alzheimer's disease (EOAD) and Late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau PET burden, and their relationship with clinical variables in amyloid-PET positive, cognitively impaired pa...

Cerebral microhemorrhage and cognition in preclinical Alzheimer’s disease

BACKGROUND: Clarifying whether incident cerebral microhemorrhages (CMHs) contribute to early cognitive or functional decline is increasingly important in the context of anti-amyloid therapies. OBJECTIVE: To determine whether incident CMHs are associated with longitudinal changes...

Plasma Phosphorylated Tau 217 Percentage by Race and Ethnicity in Preclinical Alzheimer Disease

Importance In trials targeting preclinical Alzheimer disease (AD), defined as amyloid pathology without cognitive symptoms, racial and ethnic differences in plasma phosphorylated tau 217 percentage (%p-tau217) may influence screening eligibility. Objective To characterize racial...

Sex-specific biological aging clocks across organs and omics

Sex differentially shapes aging, neurodevelopment and neurodegenerative diseases such as Alzheimer’s disease (AD). However, most biological aging clocks (artificial intelligence-predicted age minus chronological age) were trained on sex-pooled samples and implicitly assume sex in...